ISTA Pharmaceuticals: Business Overview, Financials & Competitive Analysis
ISTA Pharmaceuticals was a specialty pharmaceutical company headquartered in Irvine, California that specialized in ophthalmic drugs for inflammation, ocular pain, glaucoma, allergy, and dry eye. The company was acqui...
Get the Latest ISTA Pharmaceuticals Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeISTA Pharmaceuticals Overview
Pro stress-test →ISTA Pharmaceuticals was a specialty pharmaceutical company headquartered in Irvine, California that specialized in ophthalmic drugs for inflammation, ocular pain, glaucoma, allergy, and dry eye. The company was acquired by Bausch & Lomb in June 2012 for $500 million and subsequently became part of Valeant Pharmaceuticals in July 2013, ending independent operations.
Strategic Profile
Pro stress-test →ISTA positioned itself as a focused ophthalmic specialist with FDA-approved products (BROMDAY, BEPREVE, ISTALOL, VITRASE) and a pipeline targeting ocular inflammation, pain, and glaucoma. The acquisition by Bausch & Lomb was designed to enhance the larger company's pharmaceutical portfolio and expand its ophthalmic pipeline, complementing B+L's existing prescription and OTC eye care products.
Competitive Landscape
Pro stress-test →Prior to acquisition, ISTA competed against major pharmaceutical and specialty companies including Allergan, Alcon, Amphastar, Johnson & Johnson, Novartis, Pfizer, and Inspire Pharmaceuticals in ophthalmic markets. The company faced significant competition from generic drug manufacturers, particularly in glaucoma and anti-inflammatory categories.
Industry Context
ISTA Pharmaceuticals operates in Pharmaceuticals.
Key facts
Founded: 1992 · Headquarters: Irvine, California